CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2016—Foundation Medicine announced a three-way collaboration with Horizon Healthcare Services and Clinical Outcomes Tracking and Analysis to advance precision medicine, improve clinical outcomes, and deliver enhanced value to the health care system in the treatment of patients with metastatic non-small cell lung cancer. The organizations initiated a prospective clinical study measuring changes in survival benefit and total cost savings achieved among patients with previously untreated metastatic NSCLC who undergo comprehensive genomic profiling with FoundationOne. Based on the outcomes, the study enables Horizon to provide its members with coverage for FoundationOne as a critical component of clinical care pathways in the evaluation of patients with metastatic lung cancer.
The organizations designed the study to support guidelines from the National Comprehensive Cancer Network that specifically recommend broad molecular profiling for patients with NSCLC. These guidelines enable the identification of cancer-driving genomic alterations for which effective targeted therapies may already be approved and available commercially or to enable physicians to appropriately counsel patients regarding the availability of clinical trials.
Foundation Medicine , 617-418-2200